Boston Scientific Corporation
BSXNYSEHealthcare● Active
$48.70
+$0.15(+0.31%)
Market Cap$72.4B
P/E Ratio—
52W High$109.5
52W Low$47.17
Boston Scientific Corporation (BSX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BSX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $2.89B | $1.85B | $1.59B | $0.70B | $1.04B |
| Depreciation & Amort. | $1.37B | $1.27B | $1.20B | $1.14B | $1.09B |
| Stock-Based Comp. | $0.30B | $0.27B | $0.23B | $0.22B | $0.19B |
| Change in Working Capital | ($0.25B) | ($0.46B) | ($0.77B) | ($1.00B) | ($0.35B) |
| Net Cash from Operations | $4.53B | $3.44B | $2.50B | $1.53B | $1.87B |
| Investing Activities | |||||
| Capital Expenditure | ($0.88B) | ($0.79B) | ($0.80B) | ($0.61B) | ($0.55B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | ($0.02B) | $0.10B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.06B | $0.29B |
| Net Cash from Investing | ($2.64B) | ($5.69B) | ($2.57B) | ($2.01B) | ($1.60B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.14B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | ($0.03B) | ($0.06B) | ($0.06B) |
| Debt Issued / Repaid | ($0.49B) | $1.83B | ($0.00B) | ($0.17B) | $0.00B |
| Net Cash from Financing | ($0.40B) | $1.81B | $0.01B | ($0.55B) | ($0.10B) |
| Free Cash Flow | |||||
| Free Cash Flow | $3.66B | $2.65B | $1.70B | $0.91B | $1.32B |
| FCF Margin %(computed) | 18.22% | 15.79% | 11.96% | 7.21% | 11.07% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Boston Scientific Corporation data
About Boston Scientific Corporation (BSX) Cash Flow Statement
Boston Scientific Corporation generated operating cash flow of $4.53B and free cash flow of $3.66B for 2025 — a FCF margin of 18.22%. Capital expenditure was ($0.88B).
Frequently asked questions
BSX · 4 questionsBoston Scientific Corporation generated free cash flow of $3.66B for 2025, up 38.3% year-over-year.
BSX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10